Back

Stealth BioTherapeutics to Present at Jefferies 2015 Healthcare Conference

May 27, 2015

Presentation will be on Monday, June 1st, 2015 at 10:30 AM ET

Boston, MA – May 27, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced that Travis Wilson, Chief Executive Officer, will present a corporate overview and development update at the Jefferies 2015 Healthcare Conference in New York City. The presentation will include the latest clinical findings from Stealth’s Bendavia and Ocuvia, investigational drugs that target mitochondrial dysfunction to treat common and rare diseases. Stealth’s clinical programs were recently highlighted at the European Society of Cardiology Heart Failure Congress in Seville, Spain, during a symposium focused on mitochondria’s role in heart failure and renal disease.

The presentation will take place on Monday, June 1st, 2015 at 10:30 AM ET in New York, NY.

Mitochondria, The Cell’s Powerhouse

Mitochondria are the cell’s powerhouse, responsible for more than 90% of the energy our bodies need to sustain life and support growth. The energetics from mitochondria maintain healthy physiology and prevent disease. In many common and rare diseases, dysfunctional mitochondria are a key component of disease progression.

About Bendavia™ and Ocuvia™

Stealth’s lead candidates, Bendavia and Ocuvia, are investigational drugs with the potential to modify disease through mitoprotection — the ability to preserve energetics and restore normal energy production in mitochondria, while decreasing oxidative stress. These clinical candidates are being developed for both common and rare diseases including inherited mitochondrial diseases, where there are no FDA-approved treatments. The underlying science of Bendavia and Ocuvia is supported by more than 100 independent, peer-reviewed publications and abstracts. These mitochondrial-targeted candidates represent a novel therapeutic approach to address a wide variety of diseases having unmet treatment needs.

Stealth BioTherapeutics: Leading Mitochondrial Medicine

Stealth BioTherapeutics is a privately held biopharmaceutical company committed to bringing mitochondria therapies to patients to treat both common and rare diseases. As an important and common element in a variety of serious, debilitating diseases, mitochondria — the cell’s energy source — offer a promising, and yet untapped, target to modify diseases with significant unmet treatment needs. Stealth’s clinical development program is focused along several core therapeutic areas, including cardio-renal diseases, ophthalmic disorders and orphan mitochondrial diseases. By defining the broad potential of its mitochondrial platform and therapies, Stealth is leading mitochondrial medicine.

More information regarding Stealth and its pipeline is available at www.stealthBT.com.


Contact:

Media Relations:
dna Communications
Taylor Ramsey
Phone: (617) 520-7018
Media@StealthBT.com

Investor Relations:
Stern IR
Beth DelGiacco
Phone: (212) 362-1200
Beth@sternir.com

Media Relations

dna Communications
Kate Contreras, 617-520-7088
media@stealthbt.com

Investor Inquiries
Stern IR
Rachel Frank, 212-362-1200
IR@stealthbt.com